Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $367.74 million. The enterprise value is $108.80 million.
| Market Cap | 367.74M |
| Enterprise Value | 108.80M |
Important Dates
The last earnings date was Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RCKT has 109.77 million shares outstanding. The number of shares has increased by 8.61% in one year.
| Current Share Class | 109.77M |
| Shares Outstanding | 109.77M |
| Shares Change (YoY) | +8.61% |
| Shares Change (QoQ) | +2.12% |
| Owned by Insiders (%) | 4.04% |
| Owned by Institutions (%) | 77.67% |
| Float | 87.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 47.71 |
| PB Ratio | 0.99 |
| P/TBV Ratio | 1.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.24, with a Debt / Equity ratio of 0.07.
| Current Ratio | 9.24 |
| Quick Ratio | 9.06 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -101.42 |
Financial Efficiency
Return on equity (ROE) is -4.77% and return on invested capital (ROIC) is -31.03%.
| Return on Equity (ROE) | -4.77% |
| Return on Assets (ROA) | -28.42% |
| Return on Invested Capital (ROIC) | -31.03% |
| Return on Capital Employed (ROCE) | -48.98% |
| Weighted Average Cost of Capital (WACC) | 6.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$85,396 |
| Employee Count | 202 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RCKT has paid $8.62 million in taxes.
| Income Tax | 8.62M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.35% in the last 52 weeks. The beta is 0.50, so RCKT's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | +5.35% |
| 50-Day Moving Average | 3.57 |
| 200-Day Moving Average | 3.59 |
| Relative Strength Index (RSI) | 41.69 |
| Average Volume (20 Days) | 1,316,906 |
Short Selling Information
The latest short interest is 14.39 million, so 13.11% of the outstanding shares have been sold short.
| Short Interest | 14.39M |
| Short Previous Month | 15.50M |
| Short % of Shares Out | 13.11% |
| Short % of Float | 16.44% |
| Short Ratio (days to cover) | 9.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -191.88M |
| Pretax Income | -8.63M |
| Net Income | -17.25M |
| EBITDA | -182.18M |
| EBIT | -191.88M |
| Earnings Per Share (EPS) | -$0.15 |
Balance Sheet
The company has $283.75 million in cash and $24.80 million in debt, with a net cash position of $258.95 million or $2.36 per share.
| Cash & Cash Equivalents | 283.75M |
| Total Debt | 24.80M |
| Net Cash | 258.95M |
| Net Cash Per Share | $2.36 |
| Equity (Book Value) | 368.83M |
| Book Value Per Share | 3.37 |
| Working Capital | 258.23M |
Cash Flow
In the last 12 months, operating cash flow was -$170.27 million and capital expenditures -$127,000, giving a free cash flow of -$170.39 million.
| Operating Cash Flow | -170.27M |
| Capital Expenditures | -127,000 |
| Depreciation & Amortization | 9.71M |
| Net Borrowing | -3,000 |
| Free Cash Flow | -170.39M |
| FCF Per Share | -$1.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RCKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.61% |
| Shareholder Yield | -8.61% |
| Earnings Yield | -4.69% |
| FCF Yield | -46.33% |
Analyst Forecast
The average price target for RCKT is $8.84, which is 163.88% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.84 |
| Price Target Difference | 163.88% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |